Cardioprotective effects of ACE inhibitors : experimental proof and clinical perspectivesSCHÖLKENS, B. A; LINZ, W.Clinical physiology and biochemistry. 1990, Vol 8, pp 33-43, issn 0252-1164, 11 p., Suppl. 1Conference Paper

A specific B₂-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramiprilLINZ, W; SCHÖLKENS, B. A.British journal of pharmacology. 1992, Vol 105, Num 4, pp 771-772, issn 0007-1188Article

Contributions of animal models to understanding hypertensionLINZ, W; GANTEN, D.Progress in cardiology. 1992, Vol 5, Num 2, pp 25-36, issn 0097-109XArticle

Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in ratsLINZ, W; SCHÖLKENS, B. A; GANTEN, D et al.Clinical and experimental hypertension. Part A, Theory and practice. 1989, Vol 11, Num 7, pp 1325-1350, issn 0730-0077Article

Increased brain transcription factor expression by angiotensin in genetic hypertensionBLUME, A; LEBRUN, C. J; HERDEGEN, T et al.Hypertension (Dallas, Tex. 1979). 1997, Vol 29, Num 2, pp 592-598, issn 0194-911XArticle

Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontanously hypertensive ratsGOHLKE, P; LINZ, W; SCHÖLKENS, B. A et al.Hypertension (Dallas, Tex. 1979). 1996, Vol 28, Num 3, pp 397-402, issn 0194-911XConference Paper

Extracellular matrix deposition in hypertensive hearts. Antifibrotic effects of ramiprilNAGASAWA, K; ZIMMERMANN, R; MÜNKEL, B et al.European heart journal. 1995, Vol 16, Num MAI, pp 33-37, issn 0195-668X, SUPCConference Paper

Angiotensin-converting enzyme inhibition improves cardiac function : role of bradykininGOHLKE, P; LINZ, W; SCHÖLKENS, B. A et al.Hypertension (Dallas, Tex. 1979). 1994, Vol 23, Num 4, pp 411-418, issn 0194-911XArticle

Vascular effects of piretanide. Studies on extrarenal action in several animal modelsKLAUS, E; ALPERMANN, H. G; CASPRITZ, G et al.Arzneimittel-Forschung. 1983, Vol 33, Num 9, pp 1273-1276, issn 0004-4172Article

Does bradykinin play a role in the cardiac antiischemic effect of the ACE-inhibitors ?MARTORANA, P. A; LINZ, W; SCHOLKENS, B. A et al.Basic research in cardiology. 1991, Vol 86, Num 4, pp 293-296, issn 0300-8428Article

Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in ratsLINZ, W; HENNING, R; SCHÖLKENS, B. A et al.Journal of hypertension. 1991, Vol 9, pp S400-S401, issn 0263-6352, SUP6Conference Paper

Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissueLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Arzneimittel-Forschung. 1988, Vol 38, Num 2, pp 240-243, issn 0004-4172Article

Increase in G_iα protein accompanies progression of post-infarction remodeling in hypertensive cardiomyopathyKOUCHI, I; ZOLK, O; JOCKENHÖVEL, F et al.Hypertension (Dallas, Tex. 1979). 2000, Vol 36, Num 1, pp 42-47, issn 0194-911XArticle

Regulation of aortic atrial natriuretic factor and angiotensinogen in experimental hypertensionOGAWA, T; LINZ, W; SCHÖLKENS, B. A et al.Journal of cardiovascular pharmacology. 1998, Vol 32, Num 6, pp 1001-1008, issn 0160-2446Article

Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone ratsLINZ, W; BECKER, R. H. A; SCHÖLKENS, B. A et al.Kidney international. 1998, Vol 54, Num 6, pp 2037-2044, issn 0085-2538Conference Paper

Long-term ACE inhibition doubles lifespan of hypertensive ratsLINZ, W; JESSEN, T; BECKER, R. H. A et al.Circulation (New York, N.Y.). 1997, Vol 96, Num 9, pp 3164-3172, issn 0009-7322Article

Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusionSCHOLZ, W; ALBUS, U; COUNILLON, L et al.Cardiovascular research. 1995, Vol 29, Num 2, pp 260-268, issn 0008-6363Article

Cardiotonic activity of the water soluble forskolin derivative 8,13-epoxy-6β-(piperidinoacetoxy)-1α,7β,9β-trihydroxy-labd-14en-11-oneRAJAGOPALAN, R; GHATE, A. V; SUBBARAYAN, P et al.Arzneimittel-Forschung. 1993, Vol 43, Num 3, pp 313-319, issn 0004-4172Article

Bradykinin prevents left ventricular hypertrophy in ratsLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Journal of hypertension. Supplement. 1993, Vol 11, Num 5, pp S96-S97, issn 0952-1178Conference Paper

Renin inhibitory pentols showing improved enteral bioavailabilityKLEEMANN, H.-W; HEITSCH, H; UTZ, R et al.Journal of medicinal chemistry (Print). 1992, Vol 35, Num 3, pp 559-567, issn 0022-2623Article

Hoe 140 a new potent and long acting bradykinin-antagonist : in vitro studiesHOCK, F. J; WIRTH, K; SCHOÊLKENS, B. A et al.British journal of pharmacology. 1991, Vol 102, Num 3, pp 769-773, issn 0007-1188, 5 p.Article

High affinity binding of ramiprilat on isolated human glomeruliALBUS, U; KRESS, I; LINZ, W et al.Biochemical pharmacology. 1988, Vol 37, Num 24, pp 4679-4684, issn 0006-2952Article

Hypercholesterolemia is associated with enhanced angiotensin AT₁-receptor expressionNICKENIG, G; JUNG, O; STREHLOW, K et al.American journal of physiology. Heart and circulatory physiology. 1997, Vol 41, Num 6, pp H2701-H2707, issn 0363-6135Article

Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion productionBOULOUMIE, A; BAUERSACHS, J; LINZ, W et al.Hypertension (Dallas, Tex. 1979). 1997, Vol 30, Num 4, pp 934-941, issn 0194-911XConference Paper

Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction = Clinical interest of low dose of converting enzyme inhibitor : the HYCAR studyLINZ, W; GOHLKE, P; UNGER, T et al.Archives des maladies du coeur et des vaisseaux. 1995, Vol 88, pp 31-34, issn 0003-9683, NS2Conference Paper